PMVP
PMV Pharmaceuticals, Inc.
Next earnings Aug 5, 2026 · consensus $-0.41 EPS
Last earnings +2.2% on 2026-05-12
$1.19
▲ +3.48%$1.19▲ +11.21%
over 1Y
L $1.02EODHDH $1.80
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.5%
1W+4.4%
1M-0.8%
3M-9.2%
YTD-3.3%
1Y+11.2%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.11x).
Return on equity -74.2% · latest
PMV Pharmaceuticals, Inc. shows limited reported revenue, and -74.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M |
| Net income | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M |
| Diluted EPS | -$1.28 | -$1.61 | -$1.44 | -$1.14 | -$1.48 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$25.5M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-122.5%
FCF yield-116.0%
Quality & risk
ROIC (est.)-65.0%
Free cash flow-$73.6M
Total debt—
Net cash$38.0M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗4Period ending 2026-06-042026-06-05open ↗8-KPeriod ending 2026-06-042026-06-05open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗8-KPeriod ending 2026-05-122026-05-12open ↗SCHEDULE 13G/AFiling2026-05-04open ↗ARSPeriod ending 2025-12-312026-04-22open ↗DEFA14AFiling2026-04-22open ↗
Frequently asked
- Is PMV Pharmaceuticals, Inc. (PMVP) a buy?
- PMVP currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.11x).
- What is PMV Pharmaceuticals, Inc.'s quality score?
- PMVP scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001699382, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:19:41 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.